Want to join the conversation?
$MNK's net sales for FY15 jumped 60.8% from last year. This increase was primarily on inclusion of sales from Acthar, Ofirmev and Inomax. Specialty Generics sales increased due to higher sales of hydrocodone-related products and inclusion of full year of sales from BioVectra, partially offset by decreased sales of Methylphenidate ER.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.